Marketing new drugs is time-consuming and very expensive. Skuldtech has increased its efforts to screen existing drugs for new uses or therapeutic applications. The genomic information developed by means of Skuldtech’s bioinformatic database of biological drug targets will contribute to identifying other diseases for which a drug may be used .
In collaboration with chemical partners’ databases, Skuldtech has integrated a wide pharmacology and chemical compound knowledge database into its repurposing platform. This database is based on a detailed and exhaustive list of chemical compounds that have been published or patented and the associated information concerning in vivo and in vitro biological activities. This database includes main target families such as membrane receptors, G protein coupled receptors (GPCR), Kinases, Ion Channels, etc..
Based on the association of genomic and pharmacological knowledge and databases, Skuldtech is capable of repurposing the following drugs for new applications:
Drugs that have become public property
Drugs that have not achieved their primary clinical endpoint
This unique repurposing platform enables therapeutic modifications thanks to which Skuldtech’s biopharmaceutical sponsors can:
Reduce costs (e.g.: investments are 10 more times profitable than for Blockbuster business)
Reduce risks (e.g.: low risk of adverse toxicity and side effects)
Maintain their exclusivity (ex: patents can be obtained for new uses)
Therefore, Skuldtech’s drug repurposing platform enhances the business of drug delivery sponsors as it provides the following advantages:
Low investments leading to high returns on equity
Rapid marketing within control costs
Reduced failure risks
The method developed by Skuldtech is used for directly confirming drug targets and recognizing drug-dependent changes in gene expression, that are modulated via routes which differ from the drug’s intended target. This approach for drug target validation and the identification of secondary drug target effects is based on genome-wide gene expression patterns.
If you require any additional information concerning these drug repurposing services provided by our company, please contact our commercial department: +33(0)467 419 748.
Skuldtech is specialized in the discovery of
new Biomarkers and the development of Diagnostics
focused on personalized medicine applications.
This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics
associated with new treatments, especially in
cancer, neurodegenerative and infectious diseases.